MD Anderson has led the world as an innovator in cancer care delivery since its inception in 1944. With a focus on research-driven cancer care, MD Anderson was one of the three original comprehensive cancer centers in the 1970s. In the 1990s, MD Anderson pioneered the concept of patient-centered multidisciplinary care that delivered patient-centered clinical trials in care centers organized around the patient’s cancer condition and not around traditional medical specialties. In the 2000s, MD Anderson again innovated new methods of delivering personalized cancer therapy to the over 33,000 new patients it sees annually.
The Institute for Cancer Care Innovation has its origins in work done with Harvard Business School’s professor Michael Porter, who champions the principles of value-based health care as the cornerstone to reforming health care delivery worldwide. Porter’s work created the foundation for much of the work done by ICCI, and he also serves as the institute’s key external advisor.
Defining value in health care as the balance of the outcomes of care with the costs to deliver the care, value-based health care is becoming an international movement with broad appeal to patients, providers and payers. The partnership between MD Anderson and the Harvard Business School, including Porter’s Institute for Strategy and Competitiveness, led to projects related to measuring and reporting the outcomes of our care as well as innovative programs examining what outcomes are important to our patients. As an offshoot of that research, ICCI is developing approaches to engage patients in their care through self-reported outcomes that become part of a shared electronic medical record. ICCI also partners with others within MD Anderson to develop other ways to optimize electronic medical records to ensure it gathers better information for patients, providers, researchers and leaders within the health care system.
In conjunction with Harvard professor Robert Kaplan, ICCI is an international leader using an innovative method measuring the true costs of cancer care delivery known as time-driven activity-based costing (TDABC). Widely used in many industries, the method is now the subject of research done at MD Anderson through ICCI, representing some of the first applications of time-driven activity-based costing in health care and the first in cancer care delivery. TDABC is also crucial to helping MD Anderson create proposed bundled payments for major cancer disease sites to meet head-on the challenge of episode-based payments.
To learn more about ICCI, read its biennial report for fiscal years 2011 and 2012 here. (PDF)